ＢＥ　Azacitidine 100mg 1vial／case about 1530cases
ＢＦ　Bevacizumab (Genetical Recombination) 400mg ／ 16mL 1vial ／ case about 460cases
ＢＧ　Vedolizumab (Genetical Recombination) 300mg 1vial／case about 130cases
ＢＨ　Lyophilized Human C1-inactivator Concentrate 500　1vial／case about 380-cases
ＢＩ　Lanreotide Acetate 120mg 1syringe／case about 80cases
ＢＪ　Mepolizumab (Genetical Recombination) 100mg／1mL 1kit／case about 210cases
ＢＫ　Pomalidomide 4mg 7capsules／case about 70cases
ＢＬ　Sotatercept (Genetical Recombination) 60mg 1vial／case about 20cases
ＢＭ　Leuprorelin Acetate 22.5mg 1syringe／case about 420cases
ＢＮ　Palonosetron Hydrochloride 0.75mL／50mL 1pack／case about 1320-cases
ＢＯ　Trastuzumab Emtansine (Genetical Recombination) 160mg 1vial／case about 60cases
ＢＰ　Nivolumab (Genetical Recombination) 20mg／2mL 1vial／case about 870-cases
ＢＱ　Golimumab (Genetical Recombination) 50mg／0.5mL 1kit／case about 380cases
ＢＲ　Pomalidomide 3mg 7capsules／case about 110cases
ＢＳ　Guselkumab (Genetical Recombination) 200mg／2mL 1kit／case about 60-cases
ＢＴ　Selexipag 0.4mg 30tablets ／ case about 230cases
ＢＵ　Ofatumumab (Genetical Recombination) 20mg／0.4mL 1kit／case about 170cases
ＢＶ　Fulvestrant 250mg ／ 5mL 2syringes／case about 380cases
ＢＷ　Bevacizumab (Genetical Recombination) 400mg ／ 16mL 1vial ／ case about 1310cases
ＢＸ　Pegfilgrastim (Genetical Recombination) [Pegfilgrastim Biosimilar 1] 3.6mg／0.36mL 1syringe／case about 650-cases
ＢＹ　Rituximab (Genetical Recombination) [Rituximab Biosimilar1] 500mg／50mL 1vial／case about 660cases
ＢＺ　Elotuzumab (Genetical Recombination) 300mg 1vial／case about 240cases
ＣＡ　Panitumumab (Genetical Recombination) 400mg 1vial／case about 100-cases
ＣＢ　Atovaquone 750mg／5mL 14packs／case about 670cases
ＣＣ　Anifrolumab (Genetical Recombination) 300mg／2mL 1vial／case about 230cases
ＣＤ　Enfortumab Vedotin (Genetical Recombination) 20mg 1vial ／ case about 390cases
ＣＥ　Tazobactam Sodium-Piperacillin Sodium for Injection 4.5g 10vials ／ case about 2290cases
ＣＦ　Tildrakizumab (Genetical Recombination) 100mg 1syringe／case about 40-cases
ＣＧ　Panitumumab (Genetical Recombination) 100mg 1vial／case about 370-cases
ＣＨ　Clazosentan Sodium 150mg 10vials／case about 40cases
ＣＩ　Macitentan 10mg 30tablets ／ case about 50cases
ＣＪ　Doxorubicin Hydrochloride 20mg／10mL 1vial／case about 440cases
ＣＫ　Pomalidomide 2mg 7capsules／case about 120cases
ＣＬ　Bimekizumab (Genetical Recombination) 320mg／2mL 1kit／case about 60cases
ＣＭ　Ramucirumab (Genetical Recombination) 100mg ／ 10mL 1vial ／ case about 450cases
ＣＮ　Freeze-dried Polyethylene Glycol Treated Human Normal Immunoglobulin 5000mg 1vial／case about 510cases
ＣＯ　Tisotumab Vedotin (Genetical Recombination) 40mg 1vial／case about 80-cases
ＣＰ　Eptacog Alfa (Activated) (Genetical Recombination) 5mg 1kit／case about 50-cases

(4) Delivery period : From 1 July, 2026 through 31 March, 2027
(5) Delivery place : The University of Tsukuba Hospital
(6) Qualifications for participating in the tendering procedures : Suppliers eligible for participating in the proposed tender are those who shall :
A　not come under Article 46 and 47 of the Regulation concerning the Contract for University of Tsukuba Furthermore, minors, Person under Conservatorship or Person under Assistance that obtained the consent necessary for concluding a contract may be applicable under cases of special reasons within the said clause,
B　have the Grade A, Grade B or Grade C qualification during fiscal 2026 in the Kanto・Koshinetsu area in sales of product for participating in tenders by Single qualification for every ministry and agency,
C　prove to have obtained either the first-class license or the third-class license for selling drugs in accordance with the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices,
D　prove to have the ability to deliver the products, required by this notice, on the date and to the place specified by The Obligating Officer,
E　meet the qualification requirements which The Obligating Officer Director may specify in accordance with Article 49 of the Regulation,
F　not be currently under a suspension of business order as instructed by The Obligating Officer.
(7) Time limit of tender : 10 : 00　8 June, 2026
(8) Contact point for the notice : MURASAWA Yuki, Division of Accounting, Department of University Hospital Management, University of Tsukuba, 2―1―1 Amakubo Tsukuba-shi 305―8576 Japan, TEL 029―853―3543
(9) Please be noted that if it is indicated that environmental conditions relating to the procurement are laid down in its tender documents.

入札公告

次のとおり一般競争入札に付します。
令和８年４月16日
契約担当役
国立大学法人長岡技術科学大学
事務局長　上地　義夫

◎調達機関番号　415　◎所在地番号　15

○第２号

１　調達内容
(1)　品目分類番号　24
(2)　購入等件名及び数量
風車用試験計測システム　一式
(3)　調達件名の特質等　入札説明書による。
(4)　納入期限　令和９年１月20日
(5)　納入場所　国立大学法人長岡技術科学大学
(6)　入札方法　落札決定に当たっては、入札書に記載された金額に当該金額の10パーセントに相当する額を加算した金額（当該金額に１円未満の端数があるときは、その端数金額を切り捨てるものとする。）をもって落札価格とするので、入札者は、消費税及び地方消費税に係る課税事業者であるか免税事業者であるかを問わず、見積もった契約金額の110分の100に相当する金額を入札書に記載すること。

２　競争参加資格
(1)　国立大学法人長岡技術科学大学の契約事務取扱細則第12条の規定に該当しない者であること。なお、未成年者、被保佐人又は被補助人であって、契約締結のために必要な同意を得ている者は、同条中、特別の理由がある場合に該当する。
(2)　国の競争参加資格（全省庁統一資格）において令和８年度に関東・甲信越地域の「物品の販売」のＡ、Ｂ又はＣ等級に格付けされている者であること。
(3)　購入物品に係る迅速なアフターサービス・メンテナンスの体制が整備されていることを証明した者であること。
(4)　国立大学法人長岡技術科学大学の契約事務取扱細則第13条の規定に基づき、契約担当役が定める資格を有する者であること。
(5)　契約担当役から取引停止の措置を受けている期間中の者でないこと。